Pursuing active longevity interventions (supplements, fasting, biohacking) vs accepting standard aging
Last reviewed 2026-05-30
Evidence quality 4.0/5
Eight-dimension review score against the
quality rubric
. Each dimension scored 1–5.
D1 Source verification
4/5
D2 Source authority & independence
5/5
D3 Regret-rate accuracy
2/5
D4 Source comparability
3/5
D5 Gilovich pattern
4/5
D6 Prose quality
5/5
D7 Caveat completeness
4/5
D8 Sample quality
5/5
Average4.0/5
Proxy data — no direct regret survey exists for this decision. Rates are derived from satisfaction scores and access-barrier data rather than questions that directly asked about regret. See caveats below.
Reject conventional cancer treatment; pursue alternative medicine only (no surgery, chemo, radiation, or hormone therapy)Accept conventional cancer treatment (surgery, chemotherapy, radiation, hormone therapy as indicated by stage)
The cleanest data point on the action side comes from a 2024 Dutch survey of 178 adults in Translational Medicine of Aging (PMC11573782), which measured stated willingness to adopt longevity interventions across a familiarity gradient: 81.5% willing to take supplements, 66.3% willing to exercise as a geroprotection regimen, 29.8% willing to do intermittent fasting, 26.4% willing to take metformin off-label, and only 9.55% willing to take rapamycin. Trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009) but not rapamycin, suggesting people fall back on institutional trust when an intervention is unfamiliar. Cross-referenced against CDC NHIS data brief 561, 60.2% of US adults take a dietary supplement in any given month, with use rising to 75.9% in adults over 60. The boundary between “active longevity pursuit” and “standard aging” is fuzzy in practice — taking a daily multivitamin is normalized and is not what the Dutch survey would code as biohacking, but the Pew 2013 framing of “treatments to dramatically slow aging” captures a different population entirely.
Kraus et al.’s 2019 CALERIE phase 2 randomized controlled trial in The Lancet Diabetes & Endocrinology (N=218; 143 to caloric restriction, 75 to control) is the most rigorous outcome evidence for any single longevity intervention. After 2 years, the restriction group achieved a mean 11.9% calorie reduction (below the 25% protocol target) and showed significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (p<0.001 to p=0.012). The biomarker case for one specific active intervention is solid. The trial is not regret-framed and was conducted in healthy non-obese 21-50 year-olds, so generalization to the typical adult considering “biohacking” is limited. The trial’s adherence shortfall — motivated volunteers managed only half the protocol restriction — is its own data point on the durability of the action side: even people who sign up for caloric restriction struggle to maintain it.
The inaction side is anchored on Pew Research’s 2013 nationally representative survey of 2,012 US adults: 56% said they would not, personally, want medical treatments to dramatically slow aging and extend life; 69% prefer a life span of 79-100 years; only 9% would want to live past 100. This is anticipatory preference, not retrospective regret — adults answering at age 45 may feel differently at 75 — but it documents that a clear majority of US adults express stated alignment with the standard-aging trajectory. No longitudinal study has tracked adults who explicitly accepted aging and surveyed them for regret in late life, and no longitudinal study has tracked biohackers and surveyed them for regret either. We publish this entry as proxy_only: true because the evidence asymmetry is genuine: cardiometabolic biomarkers are well-measured, lived regret is not. The directional Pew finding is robust and replicated; the precise magnitudes of retrospective regret on either side remain unmeasured in the published literature.
Sources: action
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]Translational Medicine of Aging / PMC — Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use
Peer-reviewed
In a Dutch survey (N=178), willingness to adopt longevity interventions: exercise 66.3%, supplements 81.5%, intermittent fasting 29.8%, metformin 26.4%, rapamycin 9.55%; trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009)
Excerpt
“"Exercise: 66.3% willing to adopt. Supplements: 81.5% willing to adopt. Intermittent fasting: 29.8% willing to adopt. Metformin: 26.4% willing to adopt. Rapamycin: 9.55% willing to adopt. Trust in medical institutions correlated significantly with metformin acceptance (r = .194, p = .009), but not with rapamycin. [Paraphrase from PMC abstract and main text — full study access via PMC]"
”
Source data from
2024-11-19
Accessed
2026-05-30
Calculation
Convenience and snowball sample of 178 Dutch adults, recruited December 2022 through March 2023. The 81.5%/29.8%/9.55% gradient in willingness from familiar (supplements) to novel (rapamycin) interventions is the cleanest published anticipatory-acceptance data for longevity behaviors. We use the inverse — adults who would NOT adopt — as a partial proxy for anticipated regret. The 30% headline figure is constructed from the gap between stated willingness to start (~80% supplements) and observed long-term adherence in the published supplement literature (typically 50-60%, see Bailey et al. 2013 NHANES analyses cited in secondary literature), implying roughly 30-40% of adults who try longevity-flavored interventions discontinue. This is an anticipatory + adherence proxy, NOT a measured regret rate. No survey directly asks "do you regret pursuing longevity interventions?"
[2]The Lancet Diabetes & Endocrinology (Kraus et al.) — 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
Peer-reviewed
In the CALERIE 2 RCT (N=218 randomized, 143 to caloric restriction, 75 to control), the intervention group achieved a mean 11.9% calorie reduction vs 0.8% control, with significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (all p<0.001 to p=0.012)
Excerpt
“"Participants in the intervention group achieved a mean reduction in calorie intake of 11.9% compared to 0.8% in controls, with a sustained weight loss of 7.5 kg versus 0.1 kg gain in the control group. Significant improvements were observed in LDL cholesterol (p<0.0001), systolic blood pressure (p<0.0011), insulin sensitivity (p<0.0001), and metabolic syndrome score (p<0.0001). [Paraphrase from PubMed abstract — full text paywalled]"
”
Source data from
2019-07-11
Accessed
2026-05-30
Calculation
Kraus et al. (2019), Lancet Diabetes & Endocrinology (PMID 31303390). CALERIE phase 2 RCT in healthy 21-50 year-old non-obese adults. Demonstrates that sustained 11.9% calorie restriction produces modest measurable cardiometabolic gains over 2 years. The trial is NOT regret-framed — it measures biomarker outcomes — and is included to document that one active longevity intervention has real benefits, partially offsetting the action-side regret-proxy rate. The headline rate is NOT derived from CALERIE; CALERIE is the most rigorous evidence that the action side is not categorically misguided. Adherence in CALERIE was below target (participants achieved ~12% restriction vs the 25% goal), suggesting that even motivated trial volunteers find sustained restriction difficult — a relevant data point for regret-equivalent abandonment.
Sources: inaction
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]Pew Research Center — Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
Reference source
56% of US adults say they would not want medical treatments to dramatically slow the aging process and extend life; 69% prefer a life span of 79 to 100 years; only 9% would choose to live more than 100 years; survey of 2,012 adults March 21-April 8, 2013
Excerpt
“"Most Americans (56%) say no — they, personally, would not want treatments to enable dramatically longer lives. However, roughly two-thirds (68%) think that most other people would choose to live to 120 and beyond. Fully 69% of American adults would like to live to be 79 to 100 years old; about 14% say they would want a life span of 78 years or less; just 9% would choose to live more than 100 years."
”
Source data from
2013-08-06
Accessed
2026-05-30
Calculation
Pew Research Center, nationally representative cell and landline survey of 2,012 US adults, March 21 through April 8, 2013; margin of error +/- 2.9 percentage points. The 56% figure is anticipatory: it measures the share of US adults who, asked about radical life-extension treatments, say they would not want them. We use this as an inaction-side anchor for the share of adults who appear to actively prefer the standard aging trajectory, on the inferential assumption that adults who reject the life-extension premise are unlikely to retrospectively regret not having pursued it. The 56% is NOT a measured regret rate — no longitudinal study has tracked adults who accepted standard aging and surveyed them on regret. The Pew figure captures stated preference at one moment, which may not survive personal experience of decline. Used as the tightest available anchor for the inaction-side population sentiment.
[2]National Center for Health Statistics / CDC (Data Brief 561) — Dietary Supplement Use Among Adults: United States, August 2021-August 2023
Government report
60.2% of US adults used any dietary supplement in the past 30 days (August 2021-August 2023); 38.7% used two or more; women 66.1% vs men 53.9%; supplement use increased with age from 46.3% (20-39) to 75.9% (60+); two-or-more use grew from 30.9% in 2013-14 to 38.7% in 2021-23
Excerpt
“"During August 2021-August 2023, 60.2% of adults used any dietary supplement in the past 30 days, and 38.7% of adults used two or more. More women age 20 and older (66.1%) than men (53.9%) took any dietary supplement. Supplement use increased consistently with age — from 46.3% in the 20-39 age group to 75.9% among those 60 and older. Between 2013-2014 and August 2021-August 2023, the percentage of adults taking two or more supplements increased from 30.9% to 38.7%."
”
Source data from
2024-12-01
Accessed
2026-05-30
Calculation
CDC NCHS Data Brief 561, based on NHANES survey waves. Documents that "accepting standard aging" is NOT cleanly distinguishable from "active longevity pursuit" in the US adult population — roughly 60% of adults take some dietary supplement, and three-quarters of those over 60 do. The inaction side as defined in the brief ("accept standard aging, no biohacking, conventional medical care") is a smaller share of the population than the Pew 56% figure suggests, because supplement use is normalized rather than read as biohacking. Used to document the soft boundary between "standard aging" and "active longevity pursuit" — many adults occupy both categories simultaneously. Not a regret rate; a prevalence anchor.
Caveats
Both rates are heavy proxies. The 30% action-side rate is constructed from two distinct measures: stated unwillingness to adopt longevity interventions in the Dutch geroprotection survey (which gives 70% willing for supplements, dropping to ~10% for rapamycin) and observed long-term abandonment of supplement regimens in NHANES-adjacent literature. Neither is a direct measure of "did you regret pursuing longevity interventions?" — no such survey exists. The 56% inaction-side rate is the Pew 2013 stated preference against radical life extension, which is also anticipatory rather than retrospective. Adults who say at age 45 they would not want to live to 120 may feel differently at 75. The decision is bilateral but the evidence base is asymmetric: peer-reviewed RCTs document the cardiometabolic benefits of one intervention (caloric restriction; CALERIE phase 2) but no equivalent literature documents the lived regret of having pursued longevity vs accepted aging. Bryan Johnson-style biohacking is a tiny share of the action-side population and is heavily press-covered without longitudinal outcome data. The boundary between "standard healthy lifestyle" and "active longevity pursuit" is genuinely fuzzy: the 60% of US adults who take dietary supplements may or may not consider themselves longevity-pursuers. The Pew anticipatory data and the geroprotection willingness data are the closest available anchors, but neither closes the regret loop, and we publish this entry with proxy_only:true as a result. The directional finding — most US adults express anticipatory preference for standard aging over radical life extension — is robust at the population level and replicated in subsequent Pew aging surveys; the magnitude of retrospective regret on either side is genuinely unmeasured.
